Artificial Intelligence and Technology Collaboratory (P30 Clinical Trial Optional)
ID: 359654Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/359654

Additional Information

http://grants.nih.gov/grants/guide/rfa-files/RFA-AG-26-006.html
Timeline
    Description

    The National Institutes of Health (NIH) is inviting applications for the Artificial Intelligence and Technology Collaboratory (P30 Clinical Trial Optional) grant, aimed at promoting the development and implementation of artificial intelligence (AI) and technology in aging and Alzheimer's Disease (AD) research. This funding opportunity seeks to establish national resources and support research projects that address ethical challenges and algorithmic fairness in AI, with a focus on aging and AD-related dementias (ADRD). The NIH anticipates awarding up to four grants, each valued at $4.9 million over a five-year period, with applications due by October 15, 2025. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    RFA-AG-26-006-Full-Announcement.html
    Please provide the text you would like me to summarize.
    RFA-AG-26-006.html
    The Department of Health and Human Services, National Institutes of Health, and National Institute on Aging (NIA) are reissuing the Artificial Intelligence and Technology Collaboratory (AITC) program (RFA-AG-26-006). This funding opportunity invites Center Core (P30) applications to promote AI and technology development for aging, Alzheimer's Disease (AD), and AD-related dementias (ADRD) research. The program seeks to establish national resources, support research projects, and address ethical challenges and algorithmic fairness in AI. Collaboratories will consist of Administrative and Research Innovation Cores, with an optional Investigator-Initiated Core, and will work with a U24 Coordinating Center (RFA-AG-26-007). The NIA anticipates funding four awards of up to $4.9 million each for a five-year period. Applications are due October 15, 2025, and must demonstrate expertise in AI, technology, and aging/AD/ADRD, along with robust plans for collaboration and data sharing.
    Similar Opportunities
    Translational Center for Accelerating the Use of Digital Health Technologies Data in AD/ADRD Research
    National Institutes of Health
    The National Institutes of Health (NIH) is announcing a forthcoming funding opportunity titled "Translational Center for Accelerating the Use of Digital Health Technologies Data in AD/ADRD Research." This initiative aims to establish a comprehensive center focused on developing infrastructure and best practices for the effective use of digital health technology data in Alzheimer's Disease (AD) and related dementias research. The center will create a cloud-based, federated data repository that adheres to the FAIR principles, facilitating the secure storage, processing, and integration of diverse data types generated from AD/ADRD studies. While applications are not currently being solicited, interested parties are encouraged to prepare collaborative proposals in anticipation of the official announcement, with an estimated synopsis posting date of February 27, 2026, and a projected award date of April 25, 2027. For further inquiries, potential applicants can contact Dr. Nadezda Radoja at nadezda.radoja@nih.gov or by phone at 240-447-1938.
    Alzheimer's Drug-Development Program (U01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the Alzheimer's Drug-Development Program (Funding Opportunity Number: PAR-24-223), aimed at supporting the preclinical and early-stage clinical development of innovative drug candidates for Alzheimer's disease (AD). The program focuses on funding activities such as medicinal chemistry, pharmacokinetics, and Investigational New Drug (IND)-enabling studies, with the goal of advancing viable therapies to address the significant public health challenge posed by AD. Eligible applicants include a wide range of organizations, such as higher education institutions, nonprofits, and tribal organizations, with awards reaching up to $1.5 million over a period of up to five years for early-stage projects. Interested parties should submit their applications by November 5, 2027, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov.
    Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R21 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R21 Clinical Trial Optional)" aimed at advancing exploratory research in Alzheimer's disease (AD) and related dementias (ADRD). This initiative invites applications for innovative methodologies, animal models, and techniques that require preliminary data, with a focus on addressing health disparities among under-resourced populations. The program emphasizes the importance of interdisciplinary research to combat the public health crisis posed by AD and ADRD, with a maximum funding amount of $275,000 available over two years. Interested applicants must submit their proposals by November 16, 2027, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Institutional Training Programs to Advance Translational Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (T32 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Institutional Training Programs to Advance Translational Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (T32 Clinical Trial Not Allowed)." This initiative aims to develop a diverse, interdisciplinary workforce capable of conducting translational research on AD and ADRD, supporting training programs for predoctoral and postdoctoral researchers with varied educational backgrounds. The program emphasizes the importance of interdisciplinary collaboration and aims to enhance understanding and treatment of aging-related health issues. NIH plans to award an estimated 3-5 grants annually over the next three years, with a total budget of $2.7 million, and applications are due by September 25, 2026. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    Translational Bioinformatics and Experimental Approaches to Advance Drug Repositioning and Combination Therapy Development for Alzheimers Disease and Related Dementias (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity aimed at advancing drug repositioning and combination therapy development for Alzheimer's Disease (AD) and related dementias (ADRD). This initiative invites applications that utilize mouse models to conduct rigorous preclinical testing of FDA-approved drugs or investigational compounds, with the goal of establishing proof of concept for effective treatment strategies. Given the historical challenges in developing successful AD therapies, this program emphasizes a systematic approach and encourages collaboration between academia and industry to enhance research rigor and reproducibility. Applicants may receive up to $1 million annually, with a total funding pool of $6 million available for 4-5 awards. The application deadline is May 7, 2028, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for research on current topics in Alzheimer's disease (AD) and its related dementias (ADRD) through the R01 Clinical Trial Optional grant program. This initiative aims to support innovative research that addresses significant biomedical, social, and behavioral aspects of aging, with a focus on inclusivity and diversity in participant recruitment. Given the projected rise in expenditures for AD-related care, which could exceed $1 trillion by 2050, this funding is critical for advancing understanding and treatment of dementia-related challenges. Interested applicants can find more information and submission guidelines at the NIH grants website, with applications due by November 5, 2027, and no specific budget limits outlined.
    Illuminating AD/ADRD Genome to Enable Precision Genomic Medicine
    National Institutes of Health
    The National Institutes of Health (NIH) is announcing a forthcoming funding opportunity titled "Illuminating AD/ADRD Genome to Enable Precision Genomic Medicine," aimed at supporting integrative, cross-disciplinary research projects focused on understanding the genomic factors involved in Alzheimer's Disease (AD) and Alzheimer's Disease Related Dementias (ADRD). The initiative seeks to leverage innovative techniques and advanced analytical methods, including machine learning and comparative genomic analysis, to explore the genomic drivers of neurodegeneration through sophisticated disease models and interdisciplinary approaches. This cooperative agreement does not require cost sharing and is open to a wide range of eligible applicants, including non-domestic entities and tribal governments, with applications expected to be solicited starting in August 2026. For further inquiries, interested parties may contact Dr. Alison Yao at 301-827-7264 or via email at yaoal@nia.nih.gov.
    Interdisciplinary Research to Understand the Complex Biology of Resilience to Alzheimer’s and Related Dementias Disease Risk
    National Institutes of Health
    The National Institutes of Health (NIH) is announcing a forthcoming funding opportunity titled "Interdisciplinary Research to Understand the Complex Biology of Resilience to Alzheimer's and Related Dementias Disease Risk." This initiative aims to foster research that integrates epidemiologic, genomic, and mechanistic studies to uncover the molecular and cellular determinants of resilience against Alzheimer's disease (AD) and related dementias (ADRD) through data-driven, systems-based approaches, including artificial intelligence and machine learning. The program is particularly significant as it seeks to generate high-dimensional molecular data from brain and peripheral tissues, facilitating the discovery of molecular predictors of resilience across diverse populations. While applications are not currently being solicited, interested researchers are encouraged to prepare collaborative projects in anticipation of the opportunity, which is expected to utilize the U01 activity code. For further inquiries, potential applicants can contact Dr. Suzana Petanceska at petanceskas@nia.nih.gov or by phone at 301-496-9350. The estimated synopsis post date is February 26, 2026, with a projected award date of April 5, 2027.
    Early- and Late-Stage Clinical Trials for the Spectrum of Alzheimer's Disease/Alzheimer's Disease-Related Dementias and Age-Related Cognitive Decline
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) aimed at supporting early- and late-stage clinical trials focused on Alzheimer's Disease (AD), Alzheimer's Disease-Related Dementias (ADRD), and age-related cognitive decline. This initiative seeks applications that propose innovative pharmacological and non-pharmacological interventions to address cognitive, behavioral, and neuropsychiatric changes associated with these conditions, as well as studies to enhance trial design and methodologies. The funding opportunity, categorized under health-related discretionary grants, is intended for small businesses with expertise in aging research, with an estimated synopsis posting date of August 1, 2025, and a closing date for applications expected by October 5, 2025. For further inquiries, interested applicants can contact Laurie Ryan, Ph.D., at 301-496-9350 or via email at ryanl@mail.nih.gov.
    Institutional Training Programs to Advance Translational Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (T32 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Institutional Training Programs to Advance Translational Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD)" aimed at developing a diverse and interdisciplinary workforce for translational research in this critical health area. The initiative invites eligible institutions to create training programs for predoctoral and postdoctoral researchers, focusing on enhancing skills in data science, disease biology, and drug discovery, while not permitting independent clinical trials. With an anticipated budget of approximately $2.7 million annually for 3-5 awards over fiscal years 2025-2027, applications are due by September 25, 2026, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.